Leerink Partnrs Issues Optimistic Outlook for BNTC Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Equities research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Benitec Biopharma in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($0.26) per share for the quarter, up from their prior estimate of ($0.28). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($1.19) EPS.

Benitec Biopharma (NASDAQ:BNTC) last issued its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.19.

A number of other equities analysts have also recently commented on the stock. Robert W. Baird initiated coverage on shares of Benitec Biopharma in a research note on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday, March 24th. Finally, Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $24.43.

Benitec Biopharma Stock Performance

Shares of BNTC opened at $12.55 on Thursday. The stock has a market capitalization of $294.31 million, a PE ratio of -8.31 and a beta of 0.76. The company’s fifty day moving average is $12.37 and its 200 day moving average is $11.22. Benitec Biopharma has a fifty-two week low of $4.75 and a fifty-two week high of $16.90.

Hedge Funds Weigh In On Benitec Biopharma

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after acquiring an additional 20,012 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock worth $37,123,000 after purchasing an additional 2,142,643 shares during the period. MYDA Advisors LLC bought a new position in shares of Benitec Biopharma during the fourth quarter valued at approximately $632,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock valued at $24,913,000 after purchasing an additional 1,131,129 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 13,425 shares during the period. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Insider Buying and Selling at Benitec Biopharma

In other news, Director Suvretta Capital Management, L bought 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the acquisition, the director now owns 8,793,245 shares of the company’s stock, valued at $114,312,185. This represents a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by corporate insiders.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.